Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06183671
Status:
RECRUITING
Last Update Posted:
2024-02-26
First Post:
2023-11-20
Brief Title:
JX09 SADMAD in Healthy Participants
Sponsor:
Ji Xing Pharmaceuticals Australia Pty Ltd
Organization:
Ji Xing Pharmaceuticals Shanghai Co Ltd
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Multi-Part Single and Multiple Ascending Dose Study of JX09 in Healthy Adult Participants
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 randomized double-blind placebo-controlled multi-part single and multiple ascending dose study in healthy adult to test the safety tolerability pharmacokinetics pharmacodynamics and food effect of JX09 when administered to healthy adult subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None